

CLAIMS:

1. Use of lurbinectedin in the manufacture of a medicament for the treatment of a solid tumour, wherein said medicament is to be administered as a combination therapy with an immune checkpoint inhibitor to a

5
2. Use of an immune checkpoint inhibitor in the manufacture of a medicament for the treatment of a solid tumour, wherein said medicament is to be administered as a combination therapy with an immune checkpoint inhibitor to a patient in need thereof.
3. Use of lurbinectedin and an immune checkpoint inhibitor in the manufacture of a medicament for the treatment of a solid tumour, wherein said medicament is to be administered as a combination therapy with an immune checkpoint inhibitor to a patient in need thereof.

10
4. The use of any one of the preceding claims, wherein the immune checkpoint inhibitor comprises an immunoglobulin molecule, preferably an antibody, targeting an immune checkpoint molecule.

15
5. The use of any one of the preceding claims, wherein the immune checkpoint molecule is selected from CTLA-4, PD-1, and PD-L1.
6. The use of any one of the preceding claims, wherein the immune checkpoint inhibitor comprises a plurality of inhibitors targeting a plurality of immune checkpoint molecules, preferably CTLA-4 and PD-1.

20
7. The use of any one of the preceding claims wherein the immune checkpoint inhibitor comprises a monoclonal antibody which specifically binds CTLA-4, or which specifically binds PD-1, or which specifically binds PD-L1.
8. The use of claim 7 wherein the monoclonal antibody is selected from pembrolizumab, nivolumab, ipilimumab, avelumab, atezolizumab, durvalumab, cemiplimab (REGN2810), camrelizumab (SHR1210), envafolimab (KN035), sintilimab (IBI308), spartalizumab (PDR001), tislelizumab (BGB-A317), prolgolimab (BCD-100), toripalimab (JS001), dostarlimab (TSR-042, WBP-285) and tremelimumab (ticilimumab, CP-675,206).

25
9. The use of any one of the preceding claims, wherein the immune checkpoint inhibitor is atezolizumab.

30

10. The use of any one of the preceding claims, wherein the immune checkpoint inhibitor is avelumab.
11. The use of any one of the preceding claims, wherein the immune checkpoint inhibitor is pembrolizumab.
- 5 12. The use of any one of the preceding claims, wherein the immune checkpoint inhibitor is nivolumab.
13. The use of any one of the preceding claims, wherein the immune checkpoint inhibitor is ipilimumab.
- 10 14. The use of any one of the preceding claims, wherein the immune checkpoint inhibitor is dostarlimab.
- 15 15. The use of any one of the preceding claims, wherein the lurbinectedin and the immune checkpoint inhibitor are administered concurrently, separately or sequentially.
16. The use of claim 15 wherein the lurbinectedin is administered initially, followed by the immune checkpoint inhibitor.
- 15 17. The use of any one of the preceding claims, wherein multiple administrations of either the lurbinectedin, or the immune checkpoint inhibitor, or both, are given.
18. The use of any one of the preceding claims, , wherein lurbinectedin is administered by intravenous infusion.
- 20 19. The use of any one of the preceding claims , wherein the immune checkpoint inhibitor is administered by intravenous infusion.
- 25 20. The use of any one of the preceding claims, wherein the solid tumour is selected from the group consisting of prostate cancer, breast cancer, lung cancer, colorectal cancer, melanomas, bladder cancer, brain/CNS cancer, cervical cancer, oesophageal cancer, gastric cancer, head/neck cancer, kidney cancer, liver cancer, lymphomas, ovarian cancer, pancreatic cancer, and sarcomas.
21. The use of any one of the preceding claims, , wherein the solid tumour is a lung cancer, melanoma, or is breast cancer.
22. The use of any one of the preceding claims, , wherein the solid tumour expresses PD-L1.

23. The use of any one of the preceding claims, , wherein the method further comprises determining whether the tumour to be treated expresses PD-L1 prior to beginning treatment.

5 24. The use of any one of the preceding claims, , wherein the treatment results in one or more of: reduction in tumour size; delay in growth of tumour; prolongation of life of the patient; delay in disease progression; remission.

25. The use of any one of the preceding claims, wherein the treatment comprises prolonging survival of a patient having a solid tumour.

10 26. The use of any one of the preceding claims, wherein the treatment comprises delaying disease progression of a solid tumour in a patient.

27. The use of any one of the preceding claims, wherein the treatment comprises reducing or delaying growth of a solid tumour.

15 28. A method of selecting a patient having a solid tumour for combination therapy, the method comprising determining *in vitro* whether the solid tumour expresses PD-L1, and if so, selecting the patient for combination therapy wherein the combination therapy is to be administered as a combination of lurbinectedin and an immune checkpoint inhibitor.

29. A pharmaceutical package comprising lurbinectedin and an immune checkpoint inhibitor.

20 30. A pharmaceutical package comprising lurbinectedin, together with instructions for administration in combination with an immune checkpoint inhibitor.

31. A pharmaceutical package comprising an immune checkpoint inhibitor, together with instructions for administration in combination with lurbinectedin.